Antihypertensive Effect of $\gamma$-Linolenic Acid in Spontaneously Hypertensive Rats

Childebert St. Louis, Robert M.K.W. Lee, Jack Rosenfeld, and Angelica Fargas-Babjak

The effects of chronic treatments of adult (aged 16–17 weeks) spontaneously hypertensive rats (SHRs) with different doses of $\gamma$-linolenic acid (GLA) on blood pressure, heart rate, and body weight were studied. Twice-daily injection of SHRs with GLA lowered systolic blood pressure from 175±4 to 145±4 mm Hg within 1 week; systolic blood pressure in all three treated groups became stabilized in the normotensive range after 2 weeks of treatment. Control SHRs injected with olive oil showed only a transient decrease in systolic blood pressure on the third day. Heart rate and body weight were not affected by GLA treatment. Withdrawal of GLA treatment resulted in a rapid rise in systolic blood pressure within 1 day from 140±3 to 165±3 mm Hg, and it stabilized after 1 week at 191±5 mm Hg in the three experimental groups. A rapid increase in systolic blood pressure from 175±5 to 203±5 mm Hg was also observed in the control group treated with olive oil 1 day after the withdrawal of the treatment. Addition of aspirin (3 mg/kg) with the GLA treatment in olive oil abolished the antihypertensive effect of GLA. In contrast, once-daily treatment with GLA also lowered systolic blood pressure of the SHR, but blood pressure was still in the hypertensive range (170±6 mm Hg). Systolic blood pressure of control SHRs treated with olive oil was not affected. Plasma from untreated SHRs contained a small amount of GLA. One hour after the injection, the plasma level of GLA increased. We conclude that GLA when given twice daily is an effective antihypertensive agent in the SHR. (Hypertension 1992;19[suppl II]:II-111–II-115)
by guest on April 30, 2017

Acetylsalicylic Acid (ASA) was converted to acetylsalicylate. Graphic analyses showed that at pH higher than 7.0, because our high-performance liquid chromatographic analyses showed that at pH higher than 7.0, the concentration of GLA demonstrated purity of more than 95%. This was critical, such that for each rat, the total volume injected was maintained constant at 1.5 ml/kg for each injection. The control group received an equivalent amount of olive oil through injection.

Systolic BP and heart rate were measured by indirect measurement through the tail 1 hour after GLA injection, every 24 hours between 8 AM and 11 AM for the first week, and once a week for the next 5 weeks. Body weight was measured every other day. At the end of the 6-week treatment period, treatment of the rats was stopped. BP, heart rate, and body weight measurements were taken 24 hours before the termination of treatment and every other day for 2 weeks.

Once-Daily Treatment Study

Male SHRs 24–25 weeks old were divided into one control and three treatment groups (three animals per group). These rats were subjected to a once-daily intraperitoneal injection with either olive oil (control) or with one of the following dosages of GLA: 2.4 (group 1), 7.2 (group 2), or 14.4 (group 3) mg/kg/day. Total volume per injection again was maintained at 1.5 ml/kg. BP, heart rate, and body weight of these rats were measured 24 hours before the beginning of the treatment and on the first, second, fifth, seventh, and 14th day during the 2-week treatment period.

Treatment of Spontaneously Hypertensive Rats With Acetylsalicylic Acid

Twelve male SHRs 18–22 weeks old were divided into three groups (four per group). Their BP, heart rate, and body weight were assessed for 1 week before the start of the experiments. One group received 14.8 mg/kg/day of GLA in olive oil; the second group received 3.0 mg/kg/day of acetylsalicylic acid (ASA); and the third group received a combination of 3.0 mg/kg/day ASA and 14.8 mg/kg/day GLA. Intraperitoneal injections were given twice daily at 12-hour intervals at a volume of 1.5 ml/kg/injection. BP, heart rate, and body weight were measured 24 hours before and after the beginning of the injections and subsequently on days 4, 7, and 14 of the experiments. ASA (Sigma Chemical Co., St. Louis, Mo.) was dissolved in 2.37 M sodium carbonate (100 mg/ml) with constant stirring to reach a pH of 7.0 or less. This was critical, because our high-performance liquid chromatographic analyses showed that at pH higher than 7.0, ASA was converted to acetylsalicylate.

Determination of Plasma Level of γ-Linolenic Acid

Plasma concentration of GLA was determined by gas chromatography using the method of Rosenfeld et al. Blood was collected from an anesthetized (sodium pentobarbital, 35 mg/kg) adult SHR through a cannula inserted into the abdominal aorta. Plasma from this sample was used to construct a standard curve with known concentrations of added GLA. The standard curve showed a linear correlation between the amount of GLA added to plasma and the gas chromatographic response (r=0.9742, p<0.03).

To measure the plasma levels of GLA at different times after injection of GLA, we collected plasma samples in five conscious adult SHRs (24 weeks old) through a tail vein before and at 1 and 2 hours after intraperitoneal injection with 14.4 mg/kg GLA. An average of 0.5 ml plasma was obtained from each rat at each sampling. Fifty microliters of plasma was added to a 16×100-mm screw-cap silanized glass vial containing 300 mg XAD-2 resin (a styrene/divinylbenzene cross-linked copolymeric resin) and 4 ml of 0.1 M phosphate buffer solution at pH 7.4. The reaction was then initiated by adding 15 µl pentadfluorobenzyl bromide in 135 µl diluent (tetrachloroethylene) and shaking the reaction mixture at ambient temperature for 20 minutes. The resin was isolated by filtration through a SupelClean cartridge fitted with a sintered disk and a Luer lock fitting. The reactor bed was washed with water until the aspirate was clear, and the resin was dried in vacuo.

The derivatized analyte was eluted from the resin by washing twice with 5 ml hexane. After the evaporation of the solvent, the residue was reconstituted in 400 µl toluene. The derivatives were determined using capillary column gas chromatography with electron-capture detection.

Statistics

Results are expressed as mean±SEM. Statistical analysis was made by one-way analysis of variance, by multiple t test for comparison of the three means, and by Student’s t test for comparison of two means. Values of p<0.05 were considered significant.

Results

Figure 1 shows systolic BP response to twice-daily treatment with different doses of GLA. The acute antihypertensive effect of GLA was already evident on the third day of treatment in all of the treated groups (Figure 1, top panel). By day 5 of treatment, systolic BP of the three treated groups had decreased from 175±4.0 mm Hg before treatment to a normotensive level (140±2 mm Hg). Systolic BP of the three GLA-treated groups became stabilized at around 140±1 mm Hg after 2 weeks and remained at that level during the following 5 weeks (Figure 1, bottom panel; Table 1). Systolic BP in control SHRs injected with olive oil was also lowered on the third day after the initiation of treatment, but the decrease
was transient, because the systolic BP had returned to the pretreatment level by day 5 (Figure 1, top panel). Heart rate was not affected in any of the four groups of rats (Table 1). Body weight increased steadily, and there was no difference in body weight among the four groups of rats.

Withdrawal of treatment caused a rapid increase in systolic BP in all four groups of rats after the first day, as shown in Figure 2. Systolic BP in the three GLA groups continued to rise subsequently and reached the level of the control group after 1 week (Table 1).

To determine whether systolic BP of the rats fluctuated between treatments, we measured systolic BP twice a day (once in the morning and again in the evening) 10 hours after injection with olive oil (control) or GLA (groups 1–3) for 1 week, 3 weeks after the initiation of treatment. We found that systolic BP remained fairly constant throughout the day, suggesting a prolonged antihypertensive effect of GLA.

Figure 3 shows systolic BP response to once-daily treatment. Systolic BP was lowered gradually during the first week of treatment from the pretreatment level of greater than or equal to 190 mm Hg and became stabilized during the second week, but the systolic BP of all the GLA-treated groups was still in the hypertensive range (Table 1). In contrast, treatment with olive oil did not have any effect on systolic BP. Heart rate and body weight of the rats were also not affected by treatment.

Figure 4 shows the effect of ASA on the systolic BP of SHRs. Treatment with GLA in olive oil lowered the BP of SHRs gradually, and BP became stabilized after 1 week and remained in the normotensive range (144±10 mm Hg) after 2 weeks of treatment, as observed before. Systolic BP of SHRs treated with ASA alone remained in the range of 180 mm Hg, being 181±4 mm Hg before and 184±7 mm Hg after 2 weeks of treatment. A combination of ASA and GLA treatments prevented the antihypertensive effect of GLA. Systolic BP of the SHRs continued to rise, reaching 201±7 mm Hg at the end of 2 weeks. The systolic BP of SHRs treated with ASA alone was lowered transiently after 1 week of treatment as compared with those rats treated with a combination of ASA and GLA, but the difference disappeared at the end of 2 weeks (Figure 4).

The basal concentration of GLA in the plasma was 7.55±0.45 μg/ml. In four of five animals, the plasma level of GLA increased to 9.19±0.93 μg/ml (22% increase, p=0.03 as compared with basal level before injection) 1 hour after injection. However, 2 hours after injection, the plasma level of GLA had returned to 8.40±1.52 μg/ml (p=0.44 as compared with basal level). In one animal, the increase in the plasma level of GLA occurred at 2 hours after injection (33% increase, p=0.002).

Discussion

The major findings of this study were that twice-daily treatment with GLA can attenuate systolic BP responses in the SHR and that normotension can be achieved within 1 week even with the lowest dose of GLA. This is in contrast to a previous study in which a similar dose of GLA (approximately 1.1–2.4 mg/kg/day) was found to have no effect on resting BP in Sprague-Dawley rats and borderline hypertensive rats, even though BP response to stress due to isolation and salt loading was attenuated. The discrepancy between the two studies in response to GLA during resting conditions probably reflects the
genetic differences in fatty acid metabolism and BP regulation among different rat strains.

Because we were using bolus intraperitoneal injection of GLA in our protocol, we were concerned about the duration of the GLA effect on BP. We have found that GLA can maintain BP within the normotensive range even up to 10 hours after injection. To our knowledge, this study constitutes the first report showing that GLA can control BP in the SHR for at least 10 hours after injection. In contrast, once-daily treatment of SHRs with GLA did not reduce BP to a normotensive level. It is possible that GLA was metabolized by the SHR within 24 hours so that its effect on systolic BP did not extend beyond 24 hours.

The mechanism of action of GLA in BP regulation is largely unknown. One possible explanation is that GLA administration might increase dihomo-GLA or arachidonic acid stores in the basal condition so that under conditions of stimulated prostaglandin synthesis (e.g., stress), there is a greater production of various prostaglandins, such as prostaglandin E and I series, which are predominantly vasodilatory in function.\(^3,4\) Mills and Ward\(^3\) suggested that increased prostaglandin E biosynthesis from GLA was absent in unstressed animals because of their negative findings in Sprague-Dawley rats. Hoffmann et al\(^4\) also suggested that production of vasodilator prostaglandins may not be the only mechanism, because they

### Table 1. Physical Characteristics of Control Spontaneously Hypertensive Rats Treated With Olive Oil and Those Treated With Different Concentrations of γ-Linolenic Acid (Groups 1–3)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pretreatment</th>
<th>Week 1</th>
<th>Week 6</th>
<th>After withdrawal</th>
<th>Once-daily treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure (mm Hg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>169±5</td>
<td>175±6</td>
<td>175±4</td>
<td>199±5*</td>
<td>200±4</td>
</tr>
<tr>
<td>Group 1</td>
<td>174±4</td>
<td>145±2†</td>
<td>142±3†</td>
<td>200±4*</td>
<td>182±7</td>
</tr>
<tr>
<td>Group 2</td>
<td>178±3</td>
<td>146±2†</td>
<td>148±3†</td>
<td>199±3*</td>
<td>176±5‡</td>
</tr>
<tr>
<td>Group 3</td>
<td>175±7</td>
<td>143±4†</td>
<td>144±2†</td>
<td>190±7*</td>
<td>170±7‡</td>
</tr>
<tr>
<td>p (ANOVA)</td>
<td>0.66</td>
<td>0.0003</td>
<td>0.0001</td>
<td>0.47</td>
<td>0.01</td>
</tr>
<tr>
<td>Heart rate (min⁻¹)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>386±10</td>
<td>365±3</td>
<td>371±4</td>
<td>354±8</td>
<td>360±12</td>
</tr>
<tr>
<td>Group 1</td>
<td>389±12</td>
<td>389±3</td>
<td>364±3</td>
<td>392±11</td>
<td>364±3</td>
</tr>
<tr>
<td>Group 2</td>
<td>390±13</td>
<td>373±6</td>
<td>363±5</td>
<td>384±22</td>
<td>363±11</td>
</tr>
<tr>
<td>Group 3</td>
<td>390±14</td>
<td>353±14</td>
<td>356±9</td>
<td>384±6</td>
<td>363±17</td>
</tr>
<tr>
<td>p (ANOVA)</td>
<td>&gt;0.8</td>
<td>0.42</td>
<td>0.35</td>
<td>0.24</td>
<td>&gt;0.8</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>272±12</td>
<td>282±10</td>
<td>322±12</td>
<td>348±10</td>
<td>352±10</td>
</tr>
<tr>
<td>Group 1</td>
<td>264±4</td>
<td>280±2</td>
<td>316±4</td>
<td>356±3</td>
<td>353±6</td>
</tr>
<tr>
<td>Group 2</td>
<td>272±1</td>
<td>280±4</td>
<td>313±2</td>
<td>342±2</td>
<td>342±5</td>
</tr>
<tr>
<td>Group 3</td>
<td>269±24</td>
<td>279±24</td>
<td>306±25</td>
<td>330±24</td>
<td>319±21</td>
</tr>
<tr>
<td>p (ANOVA)</td>
<td>&gt;0.8</td>
<td>&gt;0.8</td>
<td>&gt;0.8</td>
<td>0.58</td>
<td>0.23</td>
</tr>
</tbody>
</table>

Values are mean±SEM; n=4 in each group. ANOVA, analysis of variance.

*\(p<0.01\) as compared with week 6.
†\(p<0.005\) as compared with control.
‡\(p<0.01\) as compared with after withdrawal.

---

**FIGURE 3.** Line graph shows systolic blood pressure response of adult spontaneously hypertensive rats to once-daily treatment with different concentrations of γ-linolenic acid (GLA).

**FIGURE 4.** Line graph shows effects of addition of aspirin to γ-linolenic acid (GLA) treatment on systolic blood pressure of spontaneously hypertensive rats.
have found that even though chronic treatment of young SHRs with GLA for 14 weeks through dietary means increased the tissue levels of prostaglandin I₂, there was a greater production of the potent vasoconstrictor thromboxane A₂. Our results suggest that prostaglandin synthesis might be augmented and was responsible for the antihypertensive property of GLA treatment, because inclusion of ASA with the GLA treatment was effective in abolishing the antihypertensive effect of GLA in adult SHRs. Other proposed mechanisms of action of GLA include suppression of sympathetic activity and decreased reactivity to pressor agents such as circulating catecholamines and angiotensin.⁴⁻⁶

Mills et al⁴⁻⁶ argued that olive oil did not have any effect on either systolic BP or heart rate. Our experiments showed that olive oil actually had a slight antihypertensive effect on the SHR. A possible explanation for this effect is that olive oil contains high levels of oleic acid (18:1n-9, 76%) and linoleic acid (9%).⁶ Both can be converted to GLA through the oxidative actions of dehydrogenases, so the levels of GLA could be augmented by the use of olive oil. Generally, twice- or once-daily treatment with GLA did not affect the heart rate and growth of SHRs. Previous studies in borderline hypertensive rats also showed that GLA had no effect on heart rate but may retard body weight gain.⁶

In our experiments, we have found that there was a basal level of GLA in the blood. We also found that the time course of plasma level of GLA after intraperitoneal injection was consistent with concepts of variable tissue absorption of GLA and a short plasma half-life of injected GLA. It is possible that the action of GLA is at the level of the cell membrane rather than in the blood circulation. The prolonged antihypertensive action of GLA awaits further investigation.

In conclusion, we have shown that GLA was very effective in reducing systolic BP in the SHR. The best response was obtained in a twice-daily regimen rather than a once-daily treatment.

Acknowledgment

We thank Sheila Seaman for her secretarial assistance.

References

8. Rosenfeld JM, Mureira-Russell M, Yeroushalmi S: Solid-supported reagents for the simultaneous extraction and derivatization of carboxylic acids from aqueous matrices. *J Chromatogr* 1986;358:137–146

KEY WORDS • essential hypertension • linoleic acids • antihypertensive therapy • spontaneously hypertensive rats
Antihypertensive effect of gamma-linolenic acid in spontaneously hypertensive rats.
C St Louis, R M Lee, J Rosenfeld and A Fargas-Babjak

Hypertension. 1992;19:II111
doi: 10.1161/01.HYP.19.2_Suppl.II111

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1992 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/19/2_Suppl/II111

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/